Imunon, Inc. (IMNN) is a Biotechnology company in the Healthcare sector, currently trading at $3.15. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Valuation: IMNN trades at a trailing Price-to-Earnings (P/E) of -0.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Net income is $14M (loss), growing at +24.1%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).
Balance sheet: total debt is $1M against $7M equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 2.32 (strong liquidity). Debt-to-assets is 8.2%. Total assets: $12M.
Analyst outlook: 3 / 4 analysts rate IMNN as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 75/100 (Pass), Income ?/100 (Fail).
